Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Public equity report: Cidara resets with $240M PIPE

Plus: Centessa raises $100M in first follow-on since 2021 IPO

By Paul Bonanos, Director of Biopharma Intelligence
April 27, 2024 12:18 AM UTC

A syndicate led by RA Capital Management is supplying $240 million to Cidara as the biotech marshals its resources around an influenza program to which it has reobtained full rights in a deal with J&J.

Cidara Therapeutics Inc. (NASDAQ:CDTX) has now positioned CD388, a drug-Fc conjugate for influenza A and B, as its lead program, with a Phase IIb study set to start this year. The biotech divested antifungal drug Rezzayo rezafungin to regional partner Mundipharma International Ltd. as part of its realignment...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Centessa Pharmaceuticals plc

Cidara Therapeutics Inc.